Granules India Ltd posted a strong set of numbers for Q3FY26 on Friday, January 23, with net profit rising 27.7% to ₹150.2 crore compared with ₹117.6 crore in the year-ago period, according to the company’s filing with the stock exchanges.
Revenue grew 22% to ₹1,387.9 crore, driven by robust demand across its diversified pharmaceutical portfolio.
EBITDA for the quarter increased 33.4% to ₹308.4 crore, lifting margins to 22.2% from 20.3% a year earlier. The growth was supported by the company’s mix of businesses, with finished dosages (FD) contributing 76% of revenue, while active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI) each accounted for 11%, and peptides/CDMO added 2%, the filing showed.
Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, said, “Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, ongoing R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.”
Shares of Granules India Ltd ended lower today, January 23, by 1.21% at ₹564.40 on the NSE.
Also Read: Granules India arm gets tentative approval with 180-day exclusivity for ADHD treatment drug
